Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07183501
Recruiting Not applicable

Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder

NCT07183501 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Not applicable
Started
2024-06-01
Last updated
2025-09-19

Condition(s) studied

Cesarean Section ComplicationsAbnormal Uterine Bleeding

Investigational drug(s) / intervention(s)

Combined hystroscopic and laparoscopic repair

Combined hystroscopic and laparoscopic repair: Hystroscopic isthmoplasty will be done first to ensure removal of chronically inflamed Unhealthy edges of niche, then laparoscopic exison of scar will be dine, followed by repair of the defect

Study summary

Combined hystroscopic and laparoscopic repair of symptomatic uterine Niche as new technique to maximize resolution of symptoms after niche repair with concomitant increase in RMT

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * symptomatic uterine Niche :postmenstrual spotting Exclusion Criteria: * contraindications for endoscopy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Assiut university, women health hospital Asyut Asyut Governorate Recruiting

More Assiut University trials in Egypt

Correlation Between Vaginal Laxity and Delivery Mode Recruiting
The Diagnostic Utility of T Immunoglobulin G and T Immunoglobulin M Biomarkers in Patients With Systemic Lupus Erythematosus Disease : Associations With Disease Activity and Damage Starting soon
Donor Site Morbidity After Free Vascularized Fibular Graft Recruiting
Expression of Tim-3 on Neutrophils in Ankylosing Spondylitis Starting soon
Lap Adhesiolysis in Intestinal Obstruction Recruiting

Other trials for the same condition

Ultrasonographic ONSD as a Predictor of PDPH in Spinal Anesthesia for Cesarean Delivery Starting soon
Comparing Intramyometrial Tranexamic Acid and Oxytocin for Blood Loss in Cesarean Section Starting soon
Effect of a 20% Reduction in Hyperbaric Bupivacaine Dose on High Spinal Block Incidence in Cesarean Delivery Recruiting
Effect of Myofascial Release Versus Deep Friction Massage on Abdominal Recovery and Scar After Cesarean Section Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07183501 on ClinicalTrials.gov ↗ ← All trials in Egypt